Progyny

Progyny, Inc. is a fertility benefits management company. It provides fertility solutions to employers, managing IUI, in vitro fertilization (IVF), egg freezing, and other fertility treatments. It operates through one segment: fertility and pharmacy benefits solutions. It also delivers treatment services and access to the firm’s network of fertility specialist. The company was founded on April 3, 2008 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Progyny reports record growth in 2022, eyes sustained success

Progyny's exceptional performance in 2022, driven by record revenue growth and client additions, positions the company for continued success in 2023.
The company's strengths in provider network retention, strong gross margins, and strategic investments highlight its competitive advantage and growth potential.
Challenges such as tightening growth rates and margin sustainability require proactive strategies, while opportunities in market positioning and growth avenues offer promising prospects.
With a strong pipeline, focus on enhancing services, and commitment to growth, Progyny is poised to capitalize on market demand and drive further success.

Progyny reports record Q1 growth, raises 2023 guidance amid strong demand

Progyny's Q1 2023 performance reflects robust growth, operational efficiency, and a strategic focus on expanding market reach and service offerings. Despite potential challenges, the company remains optimistic about future prospects, raising guidance for 2023 and highlighting strong demand for fertility benefits.

Progyny reports record revenue and strong growth outlook for 2023

Progyny's Q2 2023 earnings call highlighted exceptional financial performance, strong operational metrics, and a positive outlook for future growth. The company's focus on quality care, cost containment, and market trends positions it well for continued success in the reproductive health industry.
With a robust PBM model, unique contracting approach, and commitment to data-driven outcomes, Progyny stands out as a leader in the sector. The expansion into menopause services and partnerships further strengthens its competitive edge and diversifies its service offerings.
While Progyny faces challenges in market penetration and operational scalability, the company's strategic strengths and growth opportunities present a promising outlook. By navigating industry challenges and leveraging emerging trends, Progyny is poised for sustained growth and innovation.

Progyny reports record Q3 earnings, eyes growth through diversification

Progyny's Q3 performance reflects robust growth, strong client relationships, and strategic expansion initiatives.
Despite challenges in Q4 and Progyny Rx contribution decline, the company is well-positioned for sustained growth.
Opportunities lie in diversifying services, addressing economic concerns, and leveraging partnerships for future expansion.
Overall, Progyny's proactive strategies and solid financial performance signal a promising outlook for continued success.

Progyny excels in 2023, eyes diversified growth in 2024

Progyny's exceptional 2023 performance and client-focused approach position it as a leader in fertility care.
While facing revenue challenges in Q1, Progyny's strategic initiatives and market opportunities offer avenues for growth.
The company's resilience in member activity and diversified revenue streams bode well for sustained success.
Progyny's expansion plans and competitive wins underscore its strong market position and growth potential.

Progyny reports strong Q1 performance, eyes growth opportunities ahead

Progyny's Q1 showed strength but faced challenges in utilization and revenue.
The company's business model demonstrated leverage and solid financial performance.
Opportunities lie in market trends, expanding services, and employer conversations.
Guidance for Q2 and full-year adjusted EBITDA indicates growth trajectory.
Progyny's focus on women's health and family building positions it for future success.

Progyny reports 9% revenue growth in Q2 2024 earnings call

Progyny delivered solid financial performance in Q2 2024, with revenue and gross profit showing healthy growth rates.
Despite challenges in forecasting and membership growth, the company's operational strengths and cash flow generation are notable.
Adjustments to revenue guidance reflect proactive management in response to market dynamics, while opportunities for growth and efficiency improvements are evident.
Overall, Progyny's Q2 performance highlights resilience and strategic focus amidst evolving market conditions.

Progyny reports mixed Q3 performance, focuses on client growth

Progyny faced challenges in member activity and gross margin in Q3 2024.
Despite this, positive selling season results and strong client commitments were noted.
Renewals and upsell activities remained robust, supporting revenue guidance.
The company's focus on care management services and cash flow stability is evident.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Progyny's stock is trailing the S&P 500 thus far in 2024 amongst macro concerns such as the Alabama court ruling on frozen embryos. However, Progyny's Q4 2023 revenue grew by 26%, and the company continues to add clients and increase the number of covered lives. With no debt and ample cash, the company authorized a share repurchase program up to $100 million.

Progyny: Long-Term Thesis Still Intact

NEW YORK, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women's health benefits solution, announced today that its Board of Directors has approved a share repurchase program to repurchase up to $100 million of its common stock. The program will be funded through available cash balances.

Progyny, Inc. Announces Share Repurchase Program

Shares of fertility-solutions firm Progyny are in the red on disappointing guidance. The company says the Alabama court ruling on in vitro fertilization won't affect it.

Progyny Stock Is Falling After Earnings. What the IVF Ruling Means for It.

Progyny, Inc. (PGNY) Q4 2023 Earnings Call Transcript

Reports Record Full Year Revenue of $1,088.6 Million, Reflecting 38% GrowthAchieves 49% Growth in Adjusted EBITDA to Record $187.1 MillionIssues Financial Guidance for 2024, Crossing the $1.3 Billion Milestone at Midpoint

Progyny, Inc. Announces Fourth Quarter 2023 Results

Accolade

This week brought another blow for reproductive rights in the U.S. An Alabama Supreme Court handed down a ruling that not only can frozen embryos be classified as “children,” but destroying them can lead to charges of wrongful death. This decision has prompted the University of Alabama at Birmingham, the state's largest healthcare provider, to cease all in vitro fertilization (IVF) treatments.

Alabama's Fertility Ruling Raises Challenges for Stocks of Fertility Benefits Providers

NEW YORK, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women's health benefits solution, will report its financial results for the quarterly period and full year ended December 31, 2023 after the close of the market on Tuesday, February 27, 2024.

Progyny, Inc. Announces Details for Its Fourth Quarter and Full Year 2023 Results Report

Mueller Industries

Skyline Corp.

One of the fun things about writing about stocks for a living is the library of content you can draw upon for inspiration. Back in June 2020, we were deep in the pandemic, so I wrote a piece about cash-rich stocks to buy for peace of mind.

3 Cash-Rich Stocks to Buy for Peace of MInd in 2024

Vistia Health brings Progyny's comprehensive suite of fertility and family building services to its clients PHILADELPHIA , Jan. 17, 2024 /PRNewswire/ -- Vistia Health, a healthcare navigator supporting whole-person health journeys, today announced that it has selected Progyny, Inc. to be the preferred fertility and family building benefits provider for Vistia Health clients. Progyny, Inc (Nasdaq: PGNY) is a leading benefits management company specializing in fertility and family building benefits solutions.

Vistia Health selects Progyny as its preferred fertility and family building benefits provider

DexCom

Toast

Important voices in the investment world predict that 2024 could be a very strong year for mid-cap stocks. Janus Henderson portfolio manager Brian Demain believes the outlook for mid caps looks favorable as rate hikes slow and cuts draw nearer.

3 Mid-Cap Stocks Poised for a Breakout in 2024

Katie Higgins has been named Chief Commercial Officer and Steven Leist has been named Chief Technology Officer Katie Higgins has been named Chief Commercial Officer and Steven Leist has been named Chief Technology Officer

Progyny Expands its Leadership Team

NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Progyny (Nasdaq: PGNY), a transformative fertility, family building, and women's health benefits solution, today announced that Pete Anevski, Progyny's Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 8:15 A.M. Pacific Time / 11:15 A.M. Eastern Time. Following the presentation, Michael Sturmer, Progyny's President, and Mark Livingston, Progyny's Chief Financial Officer, will join Mr. Anevski for a breakout session.

Progyny, Inc. to Present at 42nd Annual J.P. Morgan Healthcare Conference

Kinsale Capital Group

Lovesac Company

SoFi Technologies

SoFi and Kinsale continue to dominate their respective unique niches of the financial industry. Progyny's valuation looks cheaper now than a year ago despite its stock rising 17%.

4 Unstoppable Multibaggers to Buy in 2024 and Hold for the Next Decade

Progyny, Inc. demonstrates strong resilience and sustained growth potential in a weak macro backdrop. The company's revenue grew 37% year-over-year, beating estimates, with strong performance in fertility benefit services and pharmacy revenue. The contract with the federal government presents a major growth opportunity and the potential for upselling.

Progyny Inc.: Resilient Business Model With Strong Growth Ahead

Progyny (PGNY) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Progyny (PGNY) is an Incredible Growth Stock: 3 Reasons Why

NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions, today announced that Pete Anevski, Progyny's Chief Executive Officer, and Mark Livingston, Chief Financial Officer, will participate in a fireside chat at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on Thursday, November 16, 2023, at 10:30 A.M. Eastern Time.

Progyny, Inc. to Present at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Progyny, Inc. (NASDAQ:PGNY ) Q3 2023 Earnings Conference Call November 7, 2023 9:00 PM ET Company Participants James Hart - IR Pete Anevski - CEO Michael Sturmer - President Mark Livingston - CFO Conference Call Participants Anne Samuel - JPMorgan Scott Schoenhaus - KeyBanc Jailendra Singh - Truist Securities Sarah James - Cantor Richard Close - Canaccord Allen Lutz - Bank of America David Larsen - BTIG Operator Good day, everyone, and welcome to the Progyny, Inc. Third Quarter 2023 Earnings Call. [Operator Instructions] It is now my pleasure to turn the floor over to your host, James Hart.

Progyny, Inc. (PGNY) Q3 2023 Earnings Call Transcript

Record Quarterly Revenue of $280.9 Million, Reflecting 37% Growth Over the Prior Year PeriodRaises Full Year Revenue and Earnings GuidanceStrong Sales Season Produces 1.3 Million New Covered Lives

Progyny, Inc. Announces Third Quarter 2023 Results

The grant will provide education, access to care, and financial assistance to either a couple or individual of color on their family building journey The grant will provide education, access to care, and financial assistance to either a couple or individual of color on their family building journey

The Broken Brown Egg and Progyny Launch 2023 Awareness, Hope, and Activism Grant™ to Help BIPOC Individuals and Couples Expand Their Families

Progyny (PGNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Progyny (PGNY) Q3 Earnings Expected to Decline

Doximity

Progyny's fertility solutions continue to be far more efficient than national averages. Doximity is weathering a downturn in the ad industry but should only grow in importance.

2 Super Stocks That Could Go Parabolic

NEW YORK, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions, will report its financial results for the quarterly period ended September 30, 2023 after the close of the market on Tuesday, November 7, 2023.

Progyny, Inc. Announces Details for Its Third Quarter 2023 Results Report

There are several clear reasons to consider Progyny stock. The company's worth is overlooked, making it a sneaky value play for investors. Here's how Progyny's unique position in the industry and financial health make it an attractive acquisition target.

Progyny: 4 Reasons I Bought This Stock

Acadia Healthcare

Eagle Pharmaceuticals

NeuroBo Pharmaceuticals Inc

Amid volatility, undervalued companies with solid prospects cushion investors from market jitters, while their robust fundamentals ensure higher returns. ACHC, PGNY, EGRX and NRBO are four such stocks.

News for Progyny Stock (PGNY)